A carregar...
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia
INTRODUCTION: The treatment of relapsed/refractory (RR) CLL has been revolutionized by the advent of the new oral inhibitors of B-cell receptor (BCR) signaling and the pro-survival protein, B-cell lymphoma 2 (BCL2). Additionally, new and more potent monoclonal antibodies against CD20 have replaced/m...
Na minha lista:
| Publicado no: | Expert Opin Pharmacother |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488229/ https://ncbi.nlm.nih.gov/pubmed/28446054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14656566.2017.1324420 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|